Clinical trials: Drug Eluting Stent
Coronary Artery Disease
Tirofiban in Stenting for Long Coronary Lesion
Periprocedural myonecrosis or infarction are associated with short, intermediate, and long term adverse outcomes. Previous study indicated 12.6% of patients suffered a peri-procedural CK-MB rise by overlapping use of drug-eluting…
- Trial name
- PETITION (NCT01498003)
- Testing
- tirofiban, normal saline solution
- Where
- China
- Volunteers
- 748 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Coronary Artery Disease
Prospective, Multi-Center, Random. Study of CoStar Paclitaxel-Eluting Coronary Stent(Direct Stenting vs. Pre-Dilatation)
The primary objective of this study is to evaluate the safety and effectiveness of a direct stenting technique compared to conventional stenting with pre-dilatation strategy using the CoStar Paclitaxel-eluting coronary stent…
- Trial name
- DECIDE (NCT00440674)
- Testing
- CoStar Paclitaxel-eluting coronary stent system
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Conor Medsystems
Vascular Diseases, Stent Complication
Eluvia DES for the Patients with Femoropopliteal Artery Lesions.
This study is a multicenter, prospective, observational study, aiming to enroll 400 patients with peripheral arterial disease in the femoral-popliteal segment implanted with Eluvia stent. Each patient was followed up for 2 years.
- Trial name
- NCT05522218
- Testing
- Eluvia drug eluting stent
- Where
- China
- Volunteers
- 400 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Peripheral Vascular Diseases, Chronic Total Occlusion of Artery of the Extremities
Excellence in Peripheral Arterial Disease Treatment of Superficial Femoral Artery Disease With Drug-eluting Stents
The superficial femoral artery (SFA) is frequently involved in atherosclerosis and is the most common target of lower extremity endovascular procedures performed in patients with claudication.
- Trial name
- XLPAD DES SFA (NCT03671655)
- Testing
- Drug-eluting stent, Bare metal stent
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- North Texas Veterans Healthcare System
Atrial Fibrillation New Onset, Acute Myocardial Infarction
Stent Placement and the Risk of New-onset AF in Patients With AMI
The benefit of a drug-eluting stent (DES) in patients with acute myocardial infarction (AMI) is controversial. This study will aim to observe the effect of a DES on the risk of new-onset AF in patients with AMI.
- Trial name
- NCT03382990
- Testing
- DES or BMS
- Volunteers
- 40,000 people
- Sponsor
- Mackay Memorial Hospital
Coronary Artery Disease
The Direct III Post Market Study
The primary objective of this multicenter, single-arm, observational study is to evaluate the feasibility of a systematic direct stenting strategy with the Svelte SLENDER IDS Sirolimus-Eluting Coronary Stent-on-a-Wire Integrated…
- Trial name
- Direct III (NCT02693158)
- Where
- 8 sites in Netherlands
- Volunteers
- 440 people
- Sponsor
- Svelte Medical Systems, Inc.
Coronary Artery Disease, Coronary Disease
Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI
This study is a prospective, randomized, open-label, single-center trial designed to compare the 30 month-safety and efficacy between low-dose (5mg/dL) and high-dose (20mg/dL) rosuvastatin treatment for patients with coronary…
- Conditions
- Coronary Artery Disease, Coronary Disease, Cardiovascular Diseases
- Trial name
- ROSUVA-30 (NCT02859480)
- Testing
- Rosuvastatin 5mg, Rosuvastatin 20mg
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Korea University Anam Hospital
Coronary Heart Disease, Angioplasty, Balloon
Drug-coated Balloons and Drug-eluting Stents in Diabetic Patients
Drug-eluting stents (DES) have long been recommended as the default device for patients undergoing percutaneous coronary intervention (PCI).
- Trial name
- NCT05937230
- Testing
- Drug-coated balloon, Drug-eluting stents
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Xijing Hospital
Myocardial Infarction, Autonomic Dysfunction
The Usefulness of Assessing Heart Rate Variability in Patients With Acute Myocardial Infarction
Aims heart rate variability (HRV) assessment in patients with acute myocardial infarction who undergo primary percutaneous coronary intervention (PCI); measurement of HRV using a device approved for medical use in Europe…
- Trial name
- HeaRt-V-AMI (NCT05098977)
- Testing
- Heart rate variability measurement, Percutaneous coronary intervention
- Where
- Romania
- Volunteers
- 200 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Stable Angina
Evaluation of Vascular Regeneration After a Drug Eluting Stent Implantation
This is a prospective cohort, one center. twenty patients who will undergo percutaneous stent implantation with everolimus eluting stent will be include. The primary endpoint was the correlation between the change (baseline vs.
- Trial name
- REVER (NCT03214900)
- Volunteers
- 20 people
- Sponsor
- Hospital San Carlos, Madrid
Atrial Fibrillation, Coronary Artery Disease
LAAO With DAPT Versus Antithrombotic Therapy
This study will retrospectively review and compare clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation…
- Trial name
- NCT03310801
- Testing
- ACP or Watchman
- Volunteers
- 480 people
- Sponsor
- Korea University Anam Hospital
Coronary Artery Disease, Drug-eluting Stents
Safety and Efficacy of the Ultimaster Stent
Durable polymer was considered to be the cause of a chronic inflammatory response that leadas to impaired endothelialization of the stent strut and subsequently increases the risk of stent thrombosis.
- Trial name
- NCT05677711
- Testing
- ultimaster
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Yonsei University
Coronary Heart Disease, Percutaneous Coronary Intervention
Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction
The primary objective of this study is: comparison of a safety and effectiveness of third generation DES (biolimus A9 and everolimus) in patients with STEMI treated by primary PCI with OCT guidance.
- Trial name
- ROBUST (NCT00888758)
- Testing
- biolimus A9, everolimus
- Where
- Czechia
- Volunteers
- 400 people
- Sponsor
- Masaryk University
Diabetes Mellitus
BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL ALENDRONATE STUDY
The main objective of this study is to assess the safety, efficacy and dose response of LABR-312 administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent in reducing restenosis…
- Trial name
- BLADE (NCT02645799)
- Testing
- LABR-312
- Where
- Israel
- Volunteers
- 270 people
- Sponsor
- BIOrest Ltd.
In-stent Coronary Artery Restenosis
In-stent Restenosis in Patients With Patent Previous Bare Metal Stent
Intra-coronary stents deployment reduces the rate of angiographic restenosis as compared to Balloon angioplasty. in-stent restenosis, usually defined as ≥50 percent diameter stenosis within previously deployed stent, is most…
- Trial name
- NCT01296399
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Rambam Health Care Campus
Coronary Artery Lesions
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary…
- Trial name
- NCT03218787
- Testing
- XIENCE, DAPT
- Where
- 101 sites in United States
- Volunteers
- 2,047 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Percutaneous Coronary Intervention
Xience Registry In Complex Lesion of Acute Coronary Syndrome Patients witH Ticagrelor (RICH)
The goal of this multicenter prospective clinical cohort study is to investigate the impact of early use of low-dose Ticagrelor-based dual antiplatelet agent therapy (TDAPT) (ticagrelor 120mg daily; l-TDAPT) as compared to…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Trial name
- RICH (NCT05746416)
- Where
- South Korea
- Volunteers
- 977 people
- Sponsor
- Hanyang University Seoul Hospital
Coronary Disease
Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety
This trial aims to demonstrate the non-inferiority of the CI-CMS-005 Coronary Stent System to the study device as well as to the TAXUS™ Express2™ Drug-Eluting Coronary Stent System in in-segment late lumen loss at 9 months after…
- Trial name
- NCT00415961
- Testing
- CoStar Paclitaxel Drug-Eluting Coronary Stent System
- Where
- Japan
- Volunteers
- 120 people
- Sponsor
- Conor Medsystems
Clopidogrel Non-Responsiveness
The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol
To compare the effect of increased dosing of clopidogrel and adding cilostazol to standard dose of clopidogrel after the insertion of drug-eluting stent in patients with clopidogrel resistance
- Trial name
- 4C-DES (NCT00620646)
- Testing
- aspirin, clopidogrel, aspirin, clopidogrel, cilostazol
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Samsung Medical Center
ST Elevation Myocardial Infarction (STEMI), Acute Coronary Syndromes (ACS)
A Single-Center, Retrospective, Propensity-Score-Matched Cohort Study Comparing Drug-Coated Balloon Versus Drug-Eluting Stent for Reducing Immediate Post-Procedural Slow-Flow/No-Reflow in Acute ST-Elevation Myocardial Infarction Patients With High Thrombus Burden
This is a single-center, retrospective, propensity-score-matched observational study. It aims to compare the rate of immediate slow-flow or no-reflow after percutaneous coronary intervention (PCI) between drug-coated balloon…
- Trial name
- STEMI-DCB (NCT07806370)
- Testing
- Drug-Coated Balloon (DCB), Drug-Eluting Stent (DES)
- Where
- China
- Volunteers
- 668 people
- Sponsor
- Xijing Hospital